npj Precision Oncology (Feb 2021)

Hypermutated phenotype in gliosarcoma of the spinal cord

  • Christopher S. Hong,
  • Gregory A. Kuzmik,
  • Adam J. Kundishora,
  • Aladine A. Elsamadicy,
  • Andrew B. Koo,
  • Declan McGuone,
  • Nicholas A. Blondin,
  • Michael L. DiLuna,
  • E. Zeynep Erson-Omay

DOI
https://doi.org/10.1038/s41698-021-00143-w
Journal volume & issue
Vol. 5, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Gliosarcoma is a variant of glioblastoma with equally poor prognosis and characterized by mixed glial and mesenchymal pathology. Metastasis is not uncommon but the involvement of the spinal cord is rare, and comprehensive genetic characterization of spinal gliosarcoma is lacking. We describe a patient initially diagnosed with a low-grade brain glioma via biopsy, followed by adjuvant radiation and temozolomide treatment. Nearly 2 years after diagnosis, she developed neurological deficits from an intradural, extramedullary tumor anterior to the spinal cord at T4, which was resected and diagnosed as gliosarcoma. Whole-exome sequencing (WES) of this tumor revealed a hypermutated phenotype, characterized by somatic mutations in key DNA mismatch repair (MMR) pathway genes, an abundance of C>T transitions within the identified somatic single nucleotide variations, and microsatellite stability, together consistent with temozolomide-mediated hypermutagenesis. This is the first report of a hypermutator phenotype in gliosarcoma, which may represent a novel genomic mechanism of progression from lower grade glioma.